Compare Novartis AG (NVS) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs VanEck Vietnam ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while VanEck Vietnam ETF trades at $16.92. The key difference: Novartis AG pays a 3.17% dividend while VanEck Vietnam ETF pays none, and Novartis AG is trading nearer its 52-week high, VanEck Vietnam ETF nearer its low. Which is the better fit depends on your goals.
| NVS | VNM | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | Sector/Thematic |
52-Week High | $168.62 | $19.80 |
52-Week Low | $113.50 | $15.35 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
VNM trades at $16.84, down 2.88% on the day, reflecting a bearish technical trend with moving averages signaling strong selling pressure. The stock's current price is at a key support level of $17, with oversold RSI readings suggesting potential for a near-term bounce. Recent news highlights challenges including underperformance relative to other emerging markets and strain on Vietnam's power grid due to extreme weather.
The outlook remains cautious due to macroeconomic headwinds and geopolitical risks affecting Vietnam's market. Investment opportunity hinges on potential foreign institutional inflows following FTSE Russell's EM reclassification in September 2026. Key risks include sustained underperformance, regional instability, and domestic infrastructure pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
